Relationship between biomarkers and subsequent bleeding risk in ST-segment elevation myocardial infarction patients...

Area of Science:

• Cardiology
• Biomarkers
• Clinical Research

Background:

• Major bleeding complications in STEMI patients are associated with increased mortality, morbidity, and healthcare costs.
• Identifying patients at higher risk for bleeding after primary PCI is crucial for effective management.
• Novel biomarkers may offer incremental value in predicting bleeding risk.

Purpose of the Study:

• To investigate the association between various biomarkers and in-hospital major bleeding in STEMI patients.
• To identify specific biomarkers that can predict increased risk of bleeding after primary PCI.

Main Methods:

• Analysis of 26 biomarkers measured at enrollment in 464 STEMI patients from the HORIZONS-AMI trial.
• Investigation of the relationship between biomarker tertiles and in-hospital non-coronary artery bypass graft (non-CABG) major bleeding.
• Statistical adjustment for a pre-existing bleeding risk score.

Main Results:

• In-hospital non-CABG major bleeding occurred in 3.7% of patients.
• Increasing levels of cystatin C and D-dimer at admission were associated with higher bleeding rates.
• Elevated cystatin C (> 2.04 mg/L) and ESAM (> 34 ng/mL) levels were independently associated with increased odds of major bleeding (OR 3.13 and 3.28, respectively).

Conclusions:

• High admission levels of cystatin C and ESAM are associated with an increased risk of major bleeding in STEMI patients.
• These biomarkers may serve as potential predictors for bleeding complications post-primary PCI.
• Further research in larger cohorts is warranted to confirm the prognostic value of cystatin C and ESAM.